65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC - Concepedia

Concepedia

Publication | Open Access

65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC

DOI Full Paper Access

10

Citations

0

References

2024

Year

Solange Peters, Daniel S.W. Tan, David E. Gerber, James J. Urbanic, S.S. Ramalingam, Jin Yu, Ligang Xing, Achim Rittmeyer, T-E. Ciuleanu, Júnior Samuel Alonso de Menezes,

Immuno-Oncology Technology

No additional data available for this publication yet. Check back later!